Plantar heel pain / plantar fasciopathy · Randomized trial · 2006
Does one high-energy shockwave session help long-lasting heel pain?
In this trial, morning heel pain fell from about 7.5 to 3.9 out of 10 three months after one focused shockwave session. With a placebo session it fell from about 7.9 to 5.3. About 47% of treated people reached the study's success goal, vs 23% with placebo.
Helped more than placebo- adults with long-lasting heel pain
- 114
- session, with a numbing injection
- 1
- followed up
- 3 mo
Good to know: Funded by the device maker.
Kudo P, Dainty K, Clarfield M, et al. Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society, 2006 · Read the paper ↗
How this study worked
What happened
Heel pain with the first steps in the morning
0–10 pain scale · start and three months after one session
StartAfter 3 months
Show the numbers
| Group | People | Start | After 3 months |
|---|---|---|---|
| Focused shockwave | 53 | 7.5 | 3.9 |
| Placebo | 52 | 7.9 | 5.3 |
The treatment
Focused shockwave
Focused, 1 session
- Sessions
- 1
- Pulses
- 3,800 per session
- Strength
- 0.36mJ/mm² positive energy at the top level; 0.64 total
- Numbing
- Local anaesthetic
- Device
- Dornier Epos Ultra
- Everyone also got
- No sport or pain medicines until the 6-week visit
Compared with: A placebo session: the same procedure, with a foam cushion blocking the shockwaves
Settings are what each study used, not a prescription.
This protocol among the library’s
Each dot is a group treated with shockwaves in a study in this library, at the midpoint when the paper gave a range. The dark dots are this study.
Of the other 29 groups: 27 lower, 1 the same, 1 higher.
Of the other 69 groups: 57 lower, 2 the same, 10 higher.
Of the other 78 groups: 13 the same, 65 higher.
Energy compares only within one measure: mJ/mm² in focused waves; bar in radial waves is the device’s firing pressure, not energy in tissue. Every protocol in the library →
Who took part
114 adults with pain in one heel for over 6 months after several treatments, at four Canadian sport-medicine and orthopaedic clinics.
hollow squares: no final score
Side effects
Most felt pain during treatment despite the nerve block (79% vs 9% with placebo). Other effects, such as swelling or tingling, were few and similar in both groups.
All the numbers and the full appraisal
The results, in numbers.
114 adults at four Canadian sport-medicine and orthopaedic clinics (randomized November 2000–December 2002) with unilateral plantar fasciitis for more than 6 months, morning first-steps pain >5 on VAS and Roles and Maudsley 3–4, after failed NSAIDs and at least two other conservative treatments. Mean age 51.1 versus 48.8 years; women 40/58 versus 33/56; mean heel-pain history 31.3 versus 27.1 months.
People, one foot each (bilateral symptoms excluded). Assessed 58 at 3–5 days, 56 at 6 weeks, 53 at 3 months; withdrawals: pain intolerance at treatment, cancer diagnosis, 2 lost interest, 1 missed visit. Methods claim intention-to-treat, but Table 3 reports n=53.
People, one foot each. Assessed 56 at 3–5 days, 53 at 6 weeks, 52 at 3 months; 2 lost interest after 3–5 days, 1 missed the 6-week and 2 the 3-month visit. Table 3 reports n=52.
Morning first-steps pain (primary)1 reported outcome
Morning first-steps pain (primary)
VAS, pain during the first few minutes of walking in the morning VAS points (range not stated)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Focused ESWT (Epos Ultra) | 53 | 7.5 (SD 1.5) | 3.9 (SD 3.2) |
| Placebo (foam-blocked head) | 52 | 7.9 (SD 1.5) | 5.3 (SD 2.7) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Active ESWT versus placebo
Pain fell in both groups (within-group P<0.0001 each); the fall was larger with active treatment (between-group P=0.0124). The paper reports mean percentage improvements of 49.1% versus 33.3%.
Analysis details and source
Table 3 prints P<0.0001 beside the 3-month row, while the text and Discussion give 0.0124 for the between-group change; 0.0124 is kept as the comparison. No CI for the difference. Observed n 53 and 52.
Clinical success: >60% less morning pain1 reported outcome
Clinical success: >60% less morning pain
Clinical success, >60% improvement from baseline in first-steps VAS People
Active ESWT versus placebo
25 of 53 (47%) versus 12 of 52 (23%) met the study definition of success at 3 months.
Analysis details and source
Methods say "at least 60%", Results ">60%". The abstract also claims a significant success difference at 6 weeks, but no 6-week data are shown.
Pain during normal daily activity1 reported outcome
Pain during normal daily activity
VAS pain during normal daily activity VAS points (range not stated)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Focused ESWT (Epos Ultra) | 53 | 6.2 (SD 2) | 3.7 (SD 3.1) |
| Placebo (foam-blocked head) | 52 | 6 (SD 2) | 4.4 (SD 2.5) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Active ESWT versus placebo
Both groups improved; the difference did not reach the 0.05 threshold (P=0.0524).
Analysis details and source
Authors describe this as marginal significance (P<0.10).
Pain during leisure or sport1 reported outcome
Pain during leisure or sport
VAS pain during leisure/sport activity VAS points (range not stated)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Focused ESWT (Epos Ultra) | 53 | 7.4 (SD 2.4) | 3.9 (SD 3.5) |
| Placebo (foam-blocked head) | 52 | 7.7 (SD 2.1) | 5.2 (SD 2.9) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Active ESWT versus placebo
Both groups improved; the between-group difference was not significant (P=0.0904).
Analysis details and source
Observed n 53 and 52; no CI.
Pain before going to bed1 reported outcome
Pain before going to bed
VAS pain prior to bed VAS points (range not stated)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Focused ESWT (Epos Ultra) | 53 | 6.2 (SD 2.4) | 3.9 (SD 3.3) |
| Placebo (foam-blocked head) | 52 | 6.5 (SD 2.5) | 4.9 (SD 2.6) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Active ESWT versus placebo
Both groups improved; the between-group difference was not significant (P=0.0793).
Analysis details and source
Observed n 53 and 52; no CI.
Roles and Maudsley excellent or good1 reported outcome
Roles and Maudsley excellent or good
Roles and Maudsley Score (patient self-assessment of pain and activity) People
Active ESWT versus placebo
23 of 53 versus 16 of 52 rated their result excellent or good; everyone was fair or poor at baseline.
Analysis details and source
Secondary outcome; the test compares the score distribution, not only the excellent-good proportion.
AOFAS ankle–hindfoot total1 reported outcome
AOFAS ankle–hindfoot total
AOFAS ankle–hindfoot scale, total score Percent change from baseline
| Group | n | Baseline | Reported change |
|---|---|---|---|
| Focused ESWT (Epos Ultra) | 53 | — | 30.3 (SD 33.3) |
| Placebo (foam-blocked head) | 52 | — | 25.8 (SD 34.2) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Active ESWT versus placebo
Mean percentage change was similar between groups (P=0.2927). AOFAS pain-domain success (none or mild pain) was 27/53 versus 18/52 (P=0.0913).
Analysis details and source
Reported as % change (SD); a nonsignificant result does not show the treatments are equivalent.
SF-12 physical health1 reported outcome
SF-12 physical health
SF-12 Global Health Rating Scale, physical component Percent change from baseline
| Group | n | Baseline | Reported change |
|---|---|---|---|
| Focused ESWT (Epos Ultra) | 53 | — | 14.2 (SD 25.5) |
| Placebo (foam-blocked head) | 52 | — | 9.1 (SD 33.8) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Active ESWT versus placebo
No significant difference in physical (P=0.2229) or mental health change (6.8% versus 2.0%, P=0.7812); authors say the study was not powered for SF-12.
Analysis details and source
Mental component: 6.8 (SD 29.4) versus 2.0 (SD 19.1).
Pain threshold on palpation1 reported outcome
Pain threshold on palpation
Pressure threshold meter (Pain Diagnostics and Thermography) Pressure threshold (unit not stated)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Focused ESWT (Epos Ultra) | 53 | 5.7 (SD 2) | 7.2 (SD 2.5) |
| Placebo (foam-blocked head) | 52 | 6.2 (SD 2.5) | 6.3 (SD 2.3) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Active ESWT versus placebo
The tolerated pressure rose with active treatment and changed little with placebo (P=0.0027).
Analysis details and source
Higher values are read as less tenderness; the paper does not state the unit or direction explicitly.
Pain during treatment1 reported outcome
Pain during treatment
Patient report of pain during the session People
Active ESWT versus placebo
Despite the nerve block, 46 of 58 felt pain during active treatment versus 5 of 56 with placebo (Table 3: 79.3% versus 8.9%).
Analysis details and source
This difference can reveal allocation to patients.
Believed they received active treatment1 reported outcome
Believed they received active treatment
Blinding check immediately after treatment People
Active ESWT versus placebo
34 active versus 13 placebo patients believed they had received shockwaves; 22 (37.9%) versus 33 (58.9%) did not know. The authors nevertheless conclude blinding worked as well as possible.
Analysis details and source
Denominators taken as all treated (58 and 56); percentages for "did not know" match these.
How treatment was delivered
Dornier Epos Ultra focused shockwave system, single session, ultrasound localization of the focal area, therapy head coupled on the medial heel; patients prone (44.7%) or on their side (55.3%).
Energy ramped over levels 1–6 (about 50 shocks each, 60 to 210 shocks/min), then about 3,500 shocks at level 7: 0.36 mJ/mm² positive energy-flux density (ED+), stated as 0.64 mJ/mm² total ED, 240 shocks/min. About 3,800 shocks in all, approximated total 1,300 mJ/mm² (ED+) or 2,330 mJ/mm² (ED).
Medial calcaneal nerve block with 5 mL of 1% Xylocaine 15–20 minutes before the procedure, in both groups.
Identical procedure, but a thin foam cushion with ultrasound gel on the therapy head stopped shock waves entering the foot; the cushion was fitted before the patient entered the room and replaced each session.
No athletic activity or pain medication until the 6-week visit; medication diaries kept. Blinded assessments at 3–5 days, 6 weeks and 3 months, then unblinding; placebo patients with persisting symptoms were offered active treatment. 6- and 12-month and crossover data were pending analysis.
Adverse events other than pain were few and, by Fisher tests, did not differ through 3 months: edema 3.5% versus 1.8%, paresthesia 1.8% versus 0, peripheral neuritis 1.8% versus 0 (resolved), back pain 1.8% versus 0 and pruritus in one placebo patient (both judged unrelated); pain after treatment 14% versus 27.3%. Pain during treatment was 79.3% versus 8.9%. Table 3 gives percentages without counts. All sites received research grants from Dornier MedTech America, the device maker.
Author-reported: results apply only to the device settings used; the trial was not powered for SF-12; improvement with placebo may reflect natural history or placebo response.
Extractor interpretation: pain during active treatment (79.3% versus 8.9%) and the significant blinding-guess difference make patient unblinding plausible for a self-reported primary outcome.
Reporting inconsistencies: Table 3 prints P<0.0001 for the primary comparison while the text gives P=0.0124; the abstract claims a 6-week success difference without shown data; intention-to-treat is stated but Table 3 uses the 53 and 52 observed; the sample-size sentence is garbled ("should be #13").
Extractor interpretation: blinded comparison ends at 3 months; later and crossover results were pending. Device-maker funding of all sites and overlap with the earlier pivotal trial (Theodore 2004, ref. 11, with shared authors) are relevant context.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Author-reported: results apply only to the device settings used; the trial was not powered for SF-12; improvement with placebo may reflect natural history or placebo response.
- Extractor interpretation: pain during active treatment (79.3% versus 8.9%) and the significant blinding-guess difference make patient unblinding plausible for a self-reported primary outcome.
- Reporting inconsistencies: Table 3 prints P<0.0001 for the primary comparison while the text gives P=0.0124; the abstract claims a 6-week success difference without shown data; intention-to-treat is stated but Table 3 uses the 53 and 52 observed; the sample-size sentence is garbled ("should be #13").
- Extractor interpretation: blinded comparison ends at 3 months; later and crossover results were pending. Device-maker funding of all sites and overlap with the earlier pivotal trial (Theodore 2004, ref. 11, with shared authors) are relevant context.
Source-linked critical reading
Placebo-controlled double-blind randomized trial
In this four-centre Canadian trial, adults with heel pain for at least six months had a larger fall in morning pain three months after one high-energy focused shockwave session than after a placebo session, and more reached the study’s success threshold (47% versus 23%). Placebo patients also improved. Other pain, function and quality-of-life scores mostly did not differ, treatment was usually painful despite a nerve block, and the device maker funded the sites.
For chronic plantar fasciitis that has not responded to conservative care, does one high-energy focused shockwave session with the Dornier Epos Ultra reduce morning first-steps pain at 3 months more than a placebo session?
Multicentre, randomized, placebo-controlled, double-blind confirmatory trial at four Canadian sites, with a randomization scheme from Biostat International in sealed opaque envelopes and blinded assessors. 114 randomized (58 active, 56 placebo); 53 and 52 assessed at 3 months. Unblinding and crossover offer at 3 months.
114 adults at four Canadian sport-medicine and orthopaedic clinics (randomized November 2000–December 2002) with unilateral plantar fasciitis for more than 6 months, morning first-steps pain >5 on VAS and Roles and Maudsley 3–4, after failed NSAIDs and at least two other conservative treatments. Mean age 51.1 versus 48.8 years; women 40/58 versus 33/56; mean heel-pain history 31.3 versus 27.1 months.
One session with the Dornier Epos Ultra under ultrasound localization after a medial calcaneal nerve block: energy ramped over six levels, then about 3,500 shocks at 0.36 mJ/mm² (ED+) and 240 shocks/min, about 3,800 shocks and an approximated 1,300 mJ/mm² (ED+) in total. No sport or pain medication until 6 weeks.
Placebo used the same procedure and nerve block, with a foam cushion on the therapy head blocking the shock waves. Both groups followed the same activity and medication restrictions.
Primary: change from baseline to 3 months in VAS pain during the first minutes of walking in the morning. Secondary: success (>60% improvement), VAS in daily activity, sport and before bed, AOFAS ankle–hindfoot, Roles and Maudsley, SF-12, pressure-threshold tenderness, and adverse events. Blinded visits at 3–5 days, 6 weeks and 3 months.
Morning pain fell from 7.5 to 3.9 with active treatment and from 7.9 to 5.3 with placebo; the difference in change favoured active treatment (P=0.0124; Table 3 prints P<0.0001). Success was 25/53 (47%) versus 12/52 (23%), P=0.0099, and Roles and Maudsley excellent-good 23/53 versus 16/52, P=0.0121. Other VAS items, AOFAS and SF-12 did not differ significantly.
Adverse events other than pain were few and, by Fisher tests, did not differ through 3 months: edema 3.5% versus 1.8%, paresthesia 1.8% versus 0, peripheral neuritis 1.8% versus 0 (resolved), back pain 1.8% versus 0 and pruritus in one placebo patient (both judged unrelated); pain after treatment 14% versus 27.3%. Pain during treatment was 79.3% versus 8.9%. Table 3 gives percentages without counts. All sites received research grants from Dornier MedTech America, the device maker.
Patients often felt the active treatment (pain 79.3% versus 8.9%) and guessed their group more often, which may weaken blinding of a self-reported outcome. Analyses use observed patients despite an intention-to-treat claim, the primary P value differs between text and table, the abstract cites 6-week success data that are not shown, and blinded comparison stops at 3 months. The device maker funded all sites.
Applies to adults with one painful heel for over six months after several conservative treatments, treated with this device, energy and nerve block. It does not test repeated sessions, other devices, radial shockwaves or effects beyond 3 months against placebo.
An independently funded trial with a sham that mimics treatment sensation, prespecified intention-to-treat analysis with confidence intervals, and blinded follow-up to 12 months.
Read the original article.
Randomized, placebo-controlled, double-blind clinical trial evaluating the treatment of plantar fasciitis with an extracorporeal shockwave therapy (ESWT) device: a North American confirmatory study.
Kudo P, Dainty K, Clarfield M, Coughlin L, Lavoie P, Lebrun C. · Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2006
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →